Skip to content
10-Q

Quarterly Report

LUMOS PHARMA, INC.

0001126234-23-000106

← back to feed
Filed
Nov 7, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Nov 2, 2023 7.91M sh
Short Term Investments Q3 2023 · Sep 30, 2023 $7.14M
Short Term Investments Q3 2023 · Dec 31, 2022 $11.35M
Cash And Equivalents Q3 2023 · Sep 30, 2023 $35.56M
Cash And Equivalents Q3 2023 · Dec 31, 2022 $56.01M
Current Liabilities Q3 2023 · Sep 30, 2023 $6.12M
Current Liabilities Q3 2023 · Dec 31, 2022 $6.71M
Total Liabilities Q3 2023 · Sep 30, 2023 $12.26M
Total Liabilities Q3 2023 · Dec 31, 2022 $12.71M
Current Assets Q3 2023 · Sep 30, 2023 $47.45M
Current Assets Q3 2023 · Dec 31, 2022 $72.01M
Total Assets Q3 2023 · Sep 30, 2023 $47.75M
Total Assets Q3 2023 · Dec 31, 2022 $72.29M
Shares Diluted Q3 2023 · Sep 30, 2022 8.39M sh
Shares Diluted Q3 2023 · Sep 30, 2022 8.37M sh
Stock Repurchased Q3 2023 · Sep 30, 2022 $197K
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$20.8M
Stockholders Equity Q3 2023 · Sep 30, 2022 $67.71M
Stockholders Equity Q3 2023 · Jun 30, 2022 $74.55M
Stockholders Equity Q3 2023 · Mar 31, 2022 $81.82M
Stockholders Equity Q3 2023 · Dec 31, 2021 $88.98M
Eps Diluted Q3 2023 · Sep 30, 2022 −$0.86
Eps Diluted Q3 2023 · Sep 30, 2022 −$2.73
Eps Basic Q3 2023 · Sep 30, 2022 −$0.86
Eps Basic Q3 2023 · Sep 30, 2022 −$2.73
Sga Expense Q3 2023 · Sep 30, 2022 $3.92M
Sga Expense Q3 2023 · Sep 30, 2022 $11.22M
Rd Expense Q3 2023 · Sep 30, 2022 $4.13M
Rd Expense Q3 2023 · Sep 30, 2022 $13M
Net Income Q3 2023 · Sep 30, 2022 −$7.25M
Net Income Q3 2023 · Sep 30, 2022 −$22.82M
Net Income Q3 2023 · Jun 30, 2022 −$7.84M
Net Income Q3 2023 · Mar 31, 2022 −$7.72M
Operating Income Q3 2023 · Sep 30, 2022 −$7.55M
Operating Income Q3 2023 · Sep 30, 2022 −$23.21M
Revenue Q3 2023 · Sep 30, 2022 $497K
Revenue Q3 2023 · Sep 30, 2022 $1.01M